GC Green Cross has entered into a strategic partnership with LG CNS to establish an artificial intelligence (AI)-based smart factory. The two companies announced on the 14th that they are launching the 'Smart Operations Driven 2030' roadmap.
The core of this initiative is to automate key production lines at major manufacturing sites in Ochang, Hwasun, and Eumseong by 2030 and transition to an autonomous operation system. They plan to integrate production, logistics, quality, and equipment data to optimize process operations and gradually establish an intelligent operating system that can detect quality and equipment anomalies in advance.
Initially, an automated production line for the new subcutaneous immunoglobulin (SCIG) product, currently under development, will be established at the Ochang plant. SCIG is intended to be a follow-up product to 'Aliglo,' a treatment for immunodeficiency that is currently administered intravenously, allowing patients to self-administer without visiting a hospital.
The Hwasun plant will focus on automating the production of key vaccine formulations, including messenger RNA (mRNA) platforms and vaccines for influenza and chickenpox. The Eumseong plant plans to introduce a continuous manufacturing process for solid dosage forms to reduce processing time and enhance quality consistency.
The pharmaceutical and biopharmaceutical industry is known for its strict quality control standards from raw materials to final products, which has led to a relatively slow pace of manufacturing innovation. GC Green Cross aims to automate the entire process from raw material input to production, packaging, and logistics to ensure a stable supply of pharmaceuticals.
Shin Woong, head of operations at GC Green Cross, stated, "AI processes are the core competitiveness of the future pharmaceutical and biopharmaceutical industry," adding, "We will enhance our manufacturing competitiveness through the establishment of smart factories." Jang Min-yong, head of the chemical battery division at LG CNS, remarked, "We will support GC Green Cross's manufacturing innovation based on our smart factory capabilities."
Meanwhile, GC Green Cross is celebrating its 59th anniversary this year. Chairman Heo Il-seop evaluated in a speech earlier this month that the company has proven its competitiveness in core businesses and laid the foundation for future growth. He highlighted the growth of the immunoglobulin blood product 'Aliglo' in the U.S. market and the global expansion of its affiliates as key achievements.
Chairman Heo emphasized, "The ability to utilize AI and data is becoming a new standard for corporate competitiveness," urging all employees to actively leverage these tools to enhance productivity and efficiency and to innovate their work methods.
The core of this initiative is to automate key production lines at major manufacturing sites in Ochang, Hwasun, and Eumseong by 2030 and transition to an autonomous operation system. They plan to integrate production, logistics, quality, and equipment data to optimize process operations and gradually establish an intelligent operating system that can detect quality and equipment anomalies in advance.
Initially, an automated production line for the new subcutaneous immunoglobulin (SCIG) product, currently under development, will be established at the Ochang plant. SCIG is intended to be a follow-up product to 'Aliglo,' a treatment for immunodeficiency that is currently administered intravenously, allowing patients to self-administer without visiting a hospital.
The Hwasun plant will focus on automating the production of key vaccine formulations, including messenger RNA (mRNA) platforms and vaccines for influenza and chickenpox. The Eumseong plant plans to introduce a continuous manufacturing process for solid dosage forms to reduce processing time and enhance quality consistency.
The pharmaceutical and biopharmaceutical industry is known for its strict quality control standards from raw materials to final products, which has led to a relatively slow pace of manufacturing innovation. GC Green Cross aims to automate the entire process from raw material input to production, packaging, and logistics to ensure a stable supply of pharmaceuticals.
Shin Woong, head of operations at GC Green Cross, stated, "AI processes are the core competitiveness of the future pharmaceutical and biopharmaceutical industry," adding, "We will enhance our manufacturing competitiveness through the establishment of smart factories." Jang Min-yong, head of the chemical battery division at LG CNS, remarked, "We will support GC Green Cross's manufacturing innovation based on our smart factory capabilities."
Meanwhile, GC Green Cross is celebrating its 59th anniversary this year. Chairman Heo Il-seop evaluated in a speech earlier this month that the company has proven its competitiveness in core businesses and laid the foundation for future growth. He highlighted the growth of the immunoglobulin blood product 'Aliglo' in the U.S. market and the global expansion of its affiliates as key achievements.
Chairman Heo emphasized, "The ability to utilize AI and data is becoming a new standard for corporate competitiveness," urging all employees to actively leverage these tools to enhance productivity and efficiency and to innovate their work methods.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.